

## Curriculum Vitae    BERGMANN Michael

### Personal Data

Date and Place of Birth:        January 16, 1966, Graz, Austria  
Nationality:                        Austria  
Academic Degree:                Assoc. Professor, MD  
Affiliation:                        Medical University of Vienna (MUV), Department of Surgery  
    Währinger Gürtel 18-20, A-1090 Vienna, Austria  
Website:                        <http://www.meduniwien.ac.at/hp/chirurgie/research-laboratories-forschung/groups-and-subgroups/bergmann/>

### Academic Career History

Since 2010                        Head, Surgical Research Laboratories, Dept. of Surgery, MUV  
    Senior PI, Colorectal Team, Div of General Surgery, MUV  
Since 2008                        Specialist for Visceral Surgery  
Since 2003                        Associate Professor of Surgery, Permanent Staff Member, Div. of  
    General Surgery , Dept of Surgery, MUV  
Since 2000                        Attending Surgeon (Div. of General Surgery)  
1994 -2003                        Resident, Staff Member, Dept of Surgery, MUV  
1990-1994                        Postdoctoral Fellow, Peter Palese, Dept. of Microbiology, Mount  
    Sinai Med School, New York, USA  
1990                                 Diploma Medical Doctor, MUV

### Industry Career History

2015                                Founder, Vacthera Ges.m.b.H, Vienna, [www.vacthera.com](http://www.vacthera.com)  
2002 – 2007                        Consultant, Avir Green Hills Biotechnology, Vienna

### Awards

2017                                Best of Biotech, AWS, Vienna  
2017                                Poster Price, 4<sup>th</sup> Immunotherapy Cancer Conference, Prague  
    (presented by Längle, PhD Student)  
2003                                vFWF Habilitation Price

### Board Memberships/ Meeting Organizations

**Boards:** Austrian Society of Surgical Research since 2010

    Comprehensive Cancer Center Vienna (Scientific Adviser, Tumor Immunology Group)

    Clinical: Tumor Board Colorectal MUV, Inflammatory Bowl Disease, MUV

**Meetings:** “Bed to Benchside in Surgical Oncology” Austrian Society of Surg Res, Vienna, 2012,

    “Host responses to the viral microbiome”, Vienna, 2015

    “Translational Oncology” Sessions, Annual Meetings of the OEGMBT

### Review Activities in last 5 years

**Grants:** Cancer UK, Wissenschaftsfonds der Österr. Nationalbank, Genome British Columbia, Bürgermeisterfonds Wien,

**Reviews:** Oncotarget, Europ J Clin Investigation, Immun Letters J Mol Medicine, The FEBS Journal, Cancer Res Prevention, Clinical Colorectal Cancer, Europ. Surgery, J Transl Medicine,

### Research Interests

Tumor Immunology, Oncolytic Viruses, Telomers, Translational Mol Oncology, Colorectal Cancer

### Funded Projects (last 10 years)

<i>Period</i>	<i>Organization</i>	<i>Short title</i>	<i>Function</i>
2017-21	Ludwig Boltzmann Institute	Applied Diagnostic (oncology study panel)	Oncology Study Panel
2016	Bürgermeisterfond Wien	Rectal Cancer Biomarker	PI
2014-16	Phamenterprise, Moscow, Russia	Anticancer Drugs	PI
2010-12	Center for Biol Safety, Kasachstan	Development of recombinant influenza virus vectors	PI
2009-10	ALT Solutions Switzerland	Inhibition of telomere lengthening by antiviral drugs	PI
2005-10	EU commision Grant #518281	A replication defective Influenza A Virus vaccine	Co-PI
2008-10	EU commision Grant #44512	Intranasal H5 vaccine	Co-PI

### Invited Talks in 2016/2017

9th Tuscany Retreat on Cancer Research and Apoptosis, Chiusi, Italy	2017
European Federation for Colorectal Cancer Meeting, Vienna, Austria	2017
Trends in Influenza ( <a href="http://flutrends.org/?lang=en">http://flutrends.org/?lang=en</a> ), St. Petersburg, Russia	2017
Oncolytic Virus Immunotherapy, Cambridge Health Institute, Boston, USA	2017
Dept. Seminar, Dept. of Microbiology, Mount Sinai School of Medicine, New York, USA	2016
Robotic Surgery in Colorectal Cancer Treatment, Ges. der Ärzte, Vienna	2016
Annual Meeting of the Austrian Society of Surgical Research, Austria	2016
Weill Cornell Seminar in Surgery, Open Medical Insitute, Salzburg, Austria	2016

### Publication list since 2000:

#### Originals, First/Last/Corresponding

Gornikiewicz, A., T. Sautner, C. Brostjan, B. Schmierer, R. Függer, E. Roth, F. Mühlbacher, and **M. Bergmann**. Catecholamines upregulate lipopolysaccharide-induced IL-6 production in human microvascular endothelial cells. *FASEB-J* 2000; 14: 1093-1100.

**Bergmann M.**, I. Romirer, M. Sachet, R. Fleischhacker, A. García-Sastre, P. Palese, K. Wolff, H. Pehamberger, R. Jakesz and T. Muster. A genetically engineered influenza A virus with ras-dependent oncolytic properties. *Cancer Res.* 2001; 61: 8188-8193.

**Bergmann M**, Gornikiewicz A, Tamandl D, Exner R, Roth E, Fugger R, Gotzinger P and Sautner T. Continuous therapeutic epinephrine but not norepinephrine prolongs splanchnic IL-6 production in porcine endotoxic shock. *Shock* 2003; 20(6):575-81.

Stift A, Prager G, Selzer E, Widder J, Kandioler D, Friedl J, Teleky B, Herbst F, Wrba F and **Bergmann M**. The early response of p53-dependent proteins during radiotherapy in human rectal carcinoma and in adjacent normal tissue. *Int J Oncol.* 2003 Nov;23(5):1269-75.

Muster T, Rajtarova J, Sachet M, Unger H, Fleischhacker R, Romirer I, Grassauer A, Url A, Garcia-Sastre A, Wolff K, Pehamberger H and **Bergmann M**. Interferon resistance promotes oncolysis by influenza virus NS1-deletion mutants. *Int J Cancer* 2004; 110(1):15-21

Sturlan S, Sachet M, Baumann S, Kuznetsova I, Spittler A, **Bergmann M**. Influenza A Virus Induces an Immediate Cytotoxic Activity in All Major Subsets of Peripheral Blood Mononuclear Cells. *PLoS ONE* 2009Jan 4(1); e4122

Sachet M, Friedl J, Hassler M, Ploder M, Stary G, Stift A, **Bergmann M**. Improvement of a dendritic cell-based tumour vaccine by an influenza virus. *Eurp. J Clin Investigation* 2009; 39(11): 1000-1009.

Petricevic B, Wessner B, Sachet M, Vrbanec D, Spittler A, **Bergmann, M**. CL097, a TLR7/8 ligand, inhibits TLR-4-Dependent activation of Irak-M and BCL-3 expression. *Shock* 2009; 32(5): 484-490.

Riss S, Stift A, Meier M, Haiden E, Grünberger T, **Bergmann M**. Endo-sponge assisted treatment of anastomotic leakage following colorectal surgery. *Colorectal Dis.* 2010 Jul;12( Online):e104-8.

Stremitzer S, Bachleitner-Hofmann T, Bachleitner-Hofmann B, Gradl B, Gruenbeck M, Mittlboeck M, **Bergmann M**. Treatment of mesh graft infection following abdominal hernia repair. Risk factor evaluation, strategy and influence of the type of mesh used. A retrospective analysis of 478 operations. *World J Surg.* 2010 Jul;34(7):1702-9.

Riss S, Stift A, Kienbacher C, Dauser B, Haunold I, Kriwanek S, Radlsboek W, **Bergmann M**. Recurrent-abscess after primary successful endo-sponge assisted treatment of anastomotic leakage after rectal cancer surgery – long term results of a multicenter study. *World J Gastroenterol.* 2010 Sep 28;16(36):4570-4.

Sturlan S., Stremitzer S, Baumann S, Sachet M, Wolschek M, Egorov A, **Bergmann M**. Endogenous expression of proteases in colon cancer cells facilitate influenza A viruses mediated oncolysis. *Cancer Biology and Therapy* 2010 Sep 2;10(6).592-596

Michlmayr A, Bachleitner-Hofmann T, Baumann S, , Burghuber C, Pluschnig U, Bartsch R, Wenzel C, Altorjai G, Forstner H, Steger G, Gnant M, **Bergmann M\***, Oehler R.. Modulation of serum

complement predicts response to neoadjuvant epirubicin/doxorubicin based chemotherapy in breast cancer patients. *Br. J. Cancer* 2010; Oct 12;103(8):1201-8. (\*corresponding author)

Wolschek M, Samm E, Seper H, Sturlan S, Kuznetsova I, Schwager C, Khassidov A, Kittel C, Muster T, Egorov A, **Bergmann M**. Establishment of a chimeric, replication-deficient influenza A virus vector by modulation of splicing efficiency. *J Virol*. 2011 Mar;85(5):2469-73.

Aschacher T, Sampl S, Käser L, Bernhard D, Spittler A, Holzmann K, **Bergmann M**. The combined use of known antiviral reverse transcriptase inhibitors AZT and DDI induce anticancer effects at low concentrations. *Neoplasia*. 2012 Jan;14(1):44-53. IF 6.3

Weiss R, Sachet M, Zinngrebe J, Aschacher T, Krainer M, Hegedus B, Walczak H, **Bergmann M**. IL-24 sensitizes tumor cells to TLR3-mediated apoptosis, *Cell Death and Differentiation*, 2013 Jun;20(6):823-33. IF 8.3

Petricevic B, Längle J, Singer J, Steger G, Bartsch R, Jensen-Jarolim E, **Bergmann M**. Metastatic disease progression of HER2/neu breast cancer patients does not influence trastuzumab mediated antibody-dependent cell-mediated cytotoxicity or phagocytosis. *J Transl. Med.* 2013 Dec 12;11:307 IF 4.0

Meshcheryakova A\*, Tamandl D\*, Bajna E, Stift J, Mittlboeck M, Svoboda M, Heiden D, Stremitzer S, Jensen-Jarolim E, Grünberger T, **Bergmann M**, Mechtcheriakova D. B cells and ectopic follicular structures: novel players in anti-tumor programming with prognostic power for patients with metastatic colorectal cancer. *PLoS One*. 2014 Jun 6;9(6):e99008. (Tamandl: group member, \* equal contribution) IF 3.9

Kuznetsova I, Shurygina A-P, Wolf B, Wolschek M, Enzmann F, Sansyzybay A, Khairullin B, Sandybayev N, Stukova M, Kiselev O, Egorov A, **Bergmann M**. Adaptive mutation in NEP allows stable transgene expression in a chimeric influenza A virus vector. *J Gen. Virol.* 2014 Feb;95(Pt 2):337-49 IF 3.6

Exner R, Pulverer W, Diem M, Spaller L, Woltering L, Schreiber M, Wolf B, Sonntagbauer M, Schröder F, Stift J, Wrba F, **Bergmann M**, Weinhäusel A, Egger G. Potential of DNA methylation in rectal cancer as diagnostic and prognostic biomarkers. *Br J Cancer*. 2015 Sep 3. doi: 10.1038/bjc.2015.303. [Epub ahead of print] Exner: group member IF 5.0

Weiss R, Laengle J, Sachet M, Shurygina AP, Kiselev O, Egorov A, **Bergmann M**. Interleukin-24 inhibits influenza A virus replication in vitro through induction of toll-like receptor 3 dependent apoptosis. *Antiviral Res.* 2015 Nov;123:93-104, IF 4.9

Aschacher T, Wolf B, Enzmann F, Kienzl P, Messner B, Sampl S, Svoboda S, Mechtcheriakova D, Holzmann K and **Bergmann M** LINE-1 induces hTERT and ensures telomere maintenance in tumour cell lines. *Oncogene*. 2016 Jan 7;35(1):94-104. IF 8.6

Aschacher T, Krokhin A, Kuznetsova I, Längle J, Nebolsin V, Egorov A, **Bergmann M**. Effect of the antiviral drug Ingavirin® (Imidazolyl ethanamid pentandioic acid) on the interferon status of cell under conditions of viral infection. *Epidemiology and Infectious Diseases* 2016, 21(4)

Hock K, Laengle J, Kuznetsova I, Egorov A, Hegedus B, Dome B, Wekerle T, Sachet M, **Bergmann M**. Oncolytic influenza A virus expressing interleukin-15 decreases tumor growth in vivo. *Surgery*. 2016 Oct 21. pii: S0039-6060(16)30480-9. IF 3.3

Kuznetsova I, Arnold T, Aschacher T, Schwager C, Hegedus B, Garay T, Pleschka S, Egorov A, **Bergmann M**. Targeting an oncolytic influenza A virus to tumor tissue by elastase. *Molecular Therapy Oncolytics*, in revision

### Originals, Co Autor

Öehler R., G. Weingartmann, N. Manhart, U. Salzer, M. Meissner, W. Schlegel, A. Spittler, **M. Bergmann**, D. Kandioler, C. Oismüller, H.M. Struse and E. Roth. Polytrauma induces increased expression of pyruvate kinase in neutrophils. *Blood* 2000; 95, 1086-1092.

Böhmig G., T. Saemann, **M. Bergmann**, B. Watschinger, H. Regele, T. Windhager, F. Mühlbacher, W.H. Hörl. and G. Zlabinger. Long-term evaluation of proliferative donor antigen-specific reactivity in cadaveric kidney transplant recipients. *Transplant International* 2000; 13: 187-193.

Kandioler D., R. Zwrtek, C. Ludwig, E. Jantschek, M. Ploner, F. Hofbauer, I. Kühner, S. Kappel, F. Wrba, R. Horvath, J. Karner, K. Renner, **M. Bergmann**, J. Karner-Hanusch, R. Pötter, B. Teleky, R. Jakesz and F. Herbst. TP53 genotype but not p53 immunohistochemical results predicts response to preoperative short term radiotherapy in rectal cancer. *Ann. Surgery* 2002; 235:493-498.

Spittler A., T. Sautner, A. Gornikiewicz, N. Manhart, R. Oehler, **M. Bergmann**, R. Függer and E. Roth. Postoperative glycyl-glutamine infusion reduces immunosuppression: partial prevention of the surgery induced decrease in HLA-DR expression on monocytes. *Clin Nutr* 2001; 20:37-42.

Wolf B, Henglmüller S, Janschek E, Ilencikova D, Ludwig-Papst C, **Bergmann M**, Mannhalter C, Wrba F, and Karner-Hanusch J. Spectrum of germ-line MLH1 and MSH2 mutations in Austrian patients with hereditary nonpolyposis colorectal cancer. *Wiener Klinische Wochenschrift* 2005; 117 (7-8) 269-277

Wolf B, Gruber S, Henglmüller S, Kappel S, **Bergmann M**, Wrba F and Karner-Hanusch J. 2006. Efficiency of the revised Bethesda guidelines for the detection of mutations in mismatch repair genes in Austrian HNPCC patients. *Int J Cancer* 2006;118(6):1465-70.

Humer J, Waltenberger A, Grassauer A, Kurz M, Valencak J, Rapberger R, Hahn S, **Bergmann M**, Löwer R, Wolff K, Muster T, Mayer B and Pehamberger H. Identification of a Melanoma Marker Derived from Melanoma-Associated Endogenous Retroviruses. *Cancer Res.* 2006; 66: (3): 1658-1663

Wacheck V, Egorov A, Groiss F, Pfeiffer T, Fuehrer T, Hoeflmayer D, Kundi K, Popow-Kraupp T, Redlberger-Fritz M, Mueller CA, Cinatl J, Michaelis M, Geiler J, **Bergmann M**, Romanova J, Roethl J, Morokutti A, Wolschek M, Ferko B, Seipelt J for the FluVacc EU consortium, Dick-Gudenus R, Muster T. A novel type of live vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1. *J. Inf. Dis.* 2010, 201: 354-62.

Riss S, Stremitzer S, Riss K, Mittlböck M, **Bergmann M**, Stift A. Pelvic organ function and quality of life after anastomotic leakage following rectal cancer surgery. *Wien Klin Wochenschr.* 2011 Jan;123(1-2):53-7

Brodowicz T, Amann G, Leithner A, Sztankay A, Kainberger F, Eisterer W, Liegl-Atzwanger B, Rachbauer F, Rath T, **Bergmann M**, Funovics PT, Ploner F, Windhager R. Consensus diagnosis and therapy of soft tissue sarcoma. *Wien Klin Wochenschr.* 2012 Feb;124(3-4):85-99. Epub 2011 Oct 28.

Schauer D, Starlinger P, Reiter C, Jahn N, Zajc P, Buchberger E, Bachleitner-Hofmann T, **Bergmann M**, Stift A, Gruenberger T, Brostjan C. Intermediate Monocytes but Not TIE2-Expressing Monocytes Are a Sensitive Diagnostic Indicator for Colorectal Cancer. *PLoS One*. 2012;7(9):e44450.

Bonelli M, Ferner E, Göschl L, Blüml S, Hladik A, Karonitsch T, Kiener H, Byrne R, Niederreiter B, Steiner C, Rath E, **Bergmann M**, Smolen J, Scheinecker C. Abatacept (CTLA-4Ig) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis (RA). *Arthritis Rheum*. 2013 Mar;65(3):599-607.

Arnold T, Michlmayr A, Baumann S, Burghuber C, Pluschnig U, Bartsch R, Steger G, Gnant M, **Bergmann M**, Thomas Bachleitner-Hofmann T, Oehler R. Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer. *Europ J Clin Investigation*, 2013 Mar;43(3):286- 91.

von Karstedt S, Conti A, Nobis M, Montinaro A, Hartwig T, Lemke J, Legler K, Annewanter F, Campbell AD, Taraborrelli L, Grosse-Wilde A, Coy JF, El-Bahrawy MA, Bergmann F, Koschny R, Werner J, Ganten TM, Schweiger T, Hoetzenecker K, Kenessey I, Hegedüs B, **Bergmann M**, Hauser C, Egberts JH, Becker T, Röcken C, Kalthoff H, Trauzold A, Anderson KI, Sansom OJ, Walczak H. Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis. *Cancer Cell*. 2015 Apr 13;27(4):561-73. IF 26.3

Schweiger T, Nikolowsky C, Starlinger P, Traxler D, Zimmermann M, Birner P, Hegedüs B, Dome B, **Bergmann M**, Mildner M, Klepetko W, Hoetzenecker K, Ankersmit HJ. Stromal expression of heat-shock protein 27 is associated with worse clinical outcome in patients with colorectal cancer lung metastases. *PLoS One*. 2015 Mar 20;10(3):e0120724. IF 3.1

Rieder FJ, Gröschel C, Kastner MT, Kosulin K, Laengle J, Zadnikar R, Marculescu R, Schneider M, Lion T, **Bergmann M**, Kallay E, Steininger C. Human cytomegalovirus infection downregulates vitamin-D receptor in mammalian cells. *J Steroid Biochem Mol Biol*. 2016 Aug 9. pii: S0960-0760(16)30217-5. IF 4.0

Exner R, Sachet M, Arnold T, Zinn-Zinnenburg M, Michlmayr A, Dubsky P, Bartsch R, Steger G, Gnant M, **Bergmann M**, Bachleitner-Hofmann T, Oehler R. Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy. *Cancer Med*. 2016 Sep;5(9):2350-8. IF 2.9

Zinngrebe J, Rieser E, Taraborrelli L, Peltzer N, Hartwig T, Ren H, Kovacs I, Endres C, Draber P, Darding M, Von Karstadt S, Lembke J, Dome B, **Bergmann M**, Ferguson BJ, Walczak H, LUBAC deficiency perturbs TLR3 signalling to cause immunodeficiency and autoinflammation. *J Exp Med*. 2016 Nov 14;213(12):2671-2689 IF 11.8

Holzlechner M, Strasser K, Zareva E, Steinhäuser L, Birnleitner H, Beer A, Bergmann M, Oehler R, Marchetti-Deschmann M. In Situ Characterization of Tissue-Resident Immune Cells by MALDI Mass Spectrometry Imaging. *J Proteome Res*. 2017 Jan 6;16(1):65-76. IF 4,2

Thannesberger J, Hellinger HJ, Klymiuk I, Kastner MT, Rieder FJJ, Schneider M, Fister S, Lion T, Kosulin K, Laengle J, **Bergmann M**, Rattei T, Steininger C. Viruses comprise an extensive pool of mobile genetic elements in eukaryote cell cultures and human clinical samples. *FASEB J*. 2017 May;31(5):1987-2000 IF 5.3

Miller A, Nagy C, Knapp B, Laengle J, Groeger M, Starkl P, **Bergmann M**, Wagner O and Haschemi A. Metabolic configurations of single cells within complex tissue microenvironments. *Cell Metabolism*. In revision

## Guidelines, Book chapter, Invited Comments and Reviews, Articles in Med. Popular Press

**Bergmann M** and Sautner T. Immunologische Nebenwirkungen von Katecholaminen. Intensiv-News 2002; 6 (2):4-5.

**Bergmann M** and Sautner T. Immunomodulatory effects of vasoactive catecholamines. Wiener Klinische Wochenschrift. Wien Klin Wochenschr. 2002; Sep 30;114(17-18):752-

Muster T and **Bergmann M**. 2005. Influenza A viruses with deletions the NS1 gene - a rational design for oncolytic viruses. In „Viral Therapy of Human Cancer “ Eds: J.G. Szinkovics and J.C. Horvath. Marcel Dekker, New York. pp 575-596.

**Bergmann M**, Wolf B and Karner-Hanusch J. Hereditary colorectal cancer – guidelines for clinical routine. Eur Surg 2006; 38/1: 59-62

**Bergmann M** et al. Standard operating procedures colorectal cancer. Medical Univierstiy of Vienna. Internal guidelines. 2009

Kristo I, Stift A, **Bergmann M**, Riss S. Surgical recurrence in Crohn's disease: Are we getting better? World J Gastroenterol. 2015 May 28;21(20):6097-100.

**Bergmann M**, Längle J. Onkolytische Virustherapie bei Malignomen. Infektiologie & Gastroenterologie-Hepatologie 4/15 JATROS 2016: 21-23

Bachleitner-Hofmann T, Stalinger P, Gruber ES, Binter A, **Bergmann M**. Stellenwert der Roboterchirurgie in der minimal invasiven Therapie des Rektumkarzinoms. Hämatologie und Onkologie 2 JATROS 2017: 88-90

**Bergmann M**, Gruber ES, Starlinger P, Bachleitner-Hofmann-T. Ein Roboter als Assitenzarzt. Forum Darmkrebs 1/2017: 8

Nowikowsky K, **Bergmann M**. Autophagy regulates apoptosis on the level of the death inducing signaling complex, 2017 FEBS J, in press

## Patents

1) Genetically engineered attenuated viruses

Patent Numbers PCT/US93/03615 filed Dec 1994, US Patent 6,022,726 issued Feb 2000

Assignee: MOUNT SINAI MEDICAL SCHOOL, NEW YORK

Inventor(s): PALESE P, ENAMI M, MUSTER T, **BERGMANN M**..

2) New reassortant influenza-A virus comprising gene segments of seasonal or pandemic strain origin, a polymerase basic protein-1 gene segment, and a polymerase gene segment, useful e.g. as vaccine to prevent influenza virus infection Patent Number(s): WO2010070098-A1, Publ. Date: 24-Jun-2010, Assignee: AVIR GREEN HILLS BIOTECHNOLOGY RES DEV

Inventor(s): **BERGMANN M**; EGOROV A; MUSTER T, ROETHLE E, ROMANOVA J, WOLSCHEK M

3) New replication deficient influenza virus comprises a modified nonstructural protein (NS) segment, useful for treating tumor. Patent Number(s): WO2009007244-A2; Publ. Date: 15-Jan-2009

Assignee: AVIR GREEN HILLS BIOTECHNOLOGY RES DEV; UNIV WIEN MEDIZINISCHE;

Inventor(s): **BERGMANN M**; EGOROV A; KITTEL C, MUSTER T, WOLSCHEK M

4) New linear expression construct that is free of any amplification and/or selection sequences, useful for preparing a composition for treating or preventing infectious diseases, e.g., avian influenza virus infection . Patent Number(s): WO2009000891-A2; Publ. Date: 31 Dec 2008

Assignee: AVIR GREEN HILLS BIOTECHNOLOGY RES DEV; UNIV WIEN MEDIZINISCHE  
Inventor(s): WOLSCHEK M; EGOROV A; **BERGMANN M**, MUSTER M, KITTEL C

5) Pharmaceutical composition useful for inducing specific immune response against antigen e.g. tumor antigens or antigens of infectious pathogens like viruses, comprises antigen and adjuvant, which is apathogenic virus . Patent Number(s): WO2007016715-A2; Publ Date 15 Feb 2007  
Assignee: GREENHILLS BIOTECHNOLOGY RES DEV TRADE G  
Inventor(s): SACHET M; **BERGMANN M**; MUSTER T, EGOROV A

6) Stable influenza A virus vector. Europ. Appl. Nr. 12184041.7, Filing 12 Sept 2012  
Assignee: Med. Univ Vienna  
Inventors: **BERGMANN M**, KUZNETSOVA I

7) Tumor cell Apoptosis. Europ. Appl Nr. 12184040.9, Filing: 12 Sept 2012  
Assignee: Med Univ. Vienna  
Inventors: **BERGMANN M**, WEISS R

**Media:**

<http://www.google.at/url?sa=t&rct=j&q=&esrc=s&source=web&cd=21&ved=0CB4QFjAAOBQ&url=http%3A%2F%2Fderstandard.at%2F800937%2FVirus-als-Krebskiller&ei=8yIsVa7LNsW7sQHquYKADA&usq=AFQjCNFes4PIS7LMDTaRgYYC72bRxI9CcA&bvm=bv.90491159,d.bGQ>

Vienna, May 2017

